ENZYCHEM LIFESCIENCES CORPORATION
KOSDAQ
₩990.00
+0.00%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Low debt: debt-to-equity of 0.07.
- Current assets comfortably cover current liabilities (current ratio 14.06).
- Sales have compounded about 14% a year over five years.
!Watch-points
- Thin interest cover: operating profit covers interest only about -65.6 times.
- Return on equity is on the lower side at -13.2%.
- Return on capital employed is on the lower side at -10.2%.
- The company reported a net loss in the latest period.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
1.02
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
2 / 5
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 5 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap₩838억
Current Price₩ 990.00
High / Low₩ 1,766.00 / 966.00
Stock P/E-4.23
Book Value₩ 1,837.07
ROCE-10.21%
ROE-13.18%
Debt to Equity0.07
Current Ratio14.06
EPS₩ -234.00
PAT Margin-26.70%
ICR-65.63
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity